A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a High-Potency Topical Corticosteroid After Sclerotherapy for Reticular and Telangiectatic Veins of the Lower Extremities

Dermatol Surg. 2015 Oct;41(10):1158-63. doi: 10.1097/DSS.0000000000000467.

Abstract

Background: Although typically mild, transient, and expected, most adverse events (AEs) postsclerotherapy are inflammatory in nature.

Objective: To evaluate the effects of a high-potency topical corticosteroid (TC) applied immediately postsclerotherapy.

Materials and methods: Subjects undergoing bilateral lower extremity sclerotherapy with polidocanol had extremities randomized to a single application of betamethasone dipropionate and placebo saline solutions immediately post-treatment in a double-blind manner. Adverse events were assessed for each extremity by subjects at t = 0 (preapplication) and t = 15 (15 minutes postapplication) and by an investigator at t = 0 and t = 15, and at Days 14 and 60. Subjects and investigator evaluated efficacy with a quartile improvement scale.

Results: Sixteen female subjects completed the study. Subjects reported no statistically significant differences in AEs between TC and placebo at either t = 0 or t = 15. Investigator scores for erythema and swelling/urtication were not significantly different between groups at the same time points. Although most subjects demonstrated 26% to 75% improvement at Day 60, results were not significantly different between extremities on subject and investigator evaluation.

Conclusion: High-potency TC application immediately postsclerotherapy produced no statistically significant differences in subject- and investigator-assessed AEs and clearance rates compared with placebo. Foam sclerotherapy with polidocanol is safe and effective for the treatment of lower extremity reticular veins.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Betamethasone / analogs & derivatives*
  • Betamethasone / therapeutic use
  • Double-Blind Method
  • Female
  • Humans
  • Lower Extremity*
  • Middle Aged
  • Polidocanol
  • Polyethylene Glycols / therapeutic use
  • Postoperative Care*
  • Prospective Studies
  • Sclerosing Solutions / therapeutic use
  • Sclerotherapy*
  • Telangiectasis / therapy*

Substances

  • Anti-Inflammatory Agents
  • Sclerosing Solutions
  • Polidocanol
  • Polyethylene Glycols
  • betamethasone-17,21-dipropionate
  • Betamethasone